Exagen Inc

NASDAQ: XGN    
Share price (4/19/24): $1.37    
Market cap (4/19/24): $23.6 million
Search in Documents
Key Exhibits
External Links

Credit Agreements Filter

EX-10.1
from 8-K 7 pages Third Amendment to Loan and Security Agreement
12/34/56
EX-10.5
from 10-Q 8 pages Second Amendment to Loan and Security Agreement
12/34/56
EX-10.1
from 10-Q 2 pages Innovatus Life Sciences Lending Fund I, LP 777 Third Avenue, 25th Floor New York, Ny 10017 Attentionn: Claes Ekstrom Re: New Management Plan Ladies and Gentlemen: We Refer to That Certain Loan and Security Agreement, Dated as of September 7,
12/34/56
EX-10.36
from 10-K 11 pages First Amendment to Loan and Security Agreement
12/34/56
EX-10.32
from S-1 50 pages Loan and Security Agreement
12/34/56
EX-10.32
from DRS 50 pages Loan and Security Agreement
12/34/56
EX-10.25
from S-1/A 132 pages Term Loan Agreement Dated as of October 10, 2013 Between Exagen Diagnostics, Inc. as Borrower, the Subsidiary Guarantors From Time to Time Party Hereto, and Capital Royalty Partners II L.P., Capital Royalty Partners II – Parallel Fund “A” L.P. and Parallel Investment Opportunities Partners II L.P. as Lenders U.S. $25,000,000
12/34/56
EX-10.25
from S-1 107 pages Term Loan Agreement Dated as of October 10, 2013 Between Exagen Diagnostics, Inc. as Borrower, the Subsidiary Guarantors From Time to Time Party Hereto, and Capital Royalty Partners II L.P., Capital Royalty Partners II – Parallel Fund “A” L.P. and Parallel Investment Opportunities Partners II L.P. as Lenders U.S. $25,000,000
12/34/56
EX-10
from DRS 107 pages Term Loan Agreement Dated as of October 10, 2013 Between Exagen Diagnostics, Inc. as Borrower, the Subsidiary Guarantors From Time to Time Party Hereto, and Capital Royalty Partners II L.P., Capital Royalty Partners II – Parallel Fund “A” L.P. and Parallel Investment Opportunities Partners II L.P. as Lenders U.S. $25,000,000
12/34/56